These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 15182761)
1. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761 [TBL] [Abstract][Full Text] [Related]
2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762 [TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189 [TBL] [Abstract][Full Text] [Related]
4. Experimental animal model for anthracycline-induced heart failure. Perik PJ; van den Berg MP; de Vries EG; van Veldhuisen DJ Eur J Heart Fail; 2004 Jun; 6(4):375-6. PubMed ID: 15182760 [No Abstract] [Full Text] [Related]
5. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229 [TBL] [Abstract][Full Text] [Related]
6. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Simůnek T; Sterba M; Holecková M; Kaplanová J; Klimtová I; Adamcová M; Gersl V; Hrdina R Biometals; 2005 Apr; 18(2):163-9. PubMed ID: 15954742 [TBL] [Abstract][Full Text] [Related]
7. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Simůnek T; Klimtová I; Kaplanová J; Sterba M; Mazurová Y; Adamcová M; Hrdina R; Gersl V; Ponka P Pharmacol Res; 2005 Mar; 51(3):223-31. PubMed ID: 15661572 [TBL] [Abstract][Full Text] [Related]
8. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556 [TBL] [Abstract][Full Text] [Related]
9. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878 [TBL] [Abstract][Full Text] [Related]
10. Exposure to anthracyclines during childhood causes cardiac injury. Lipshultz SE Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284 [TBL] [Abstract][Full Text] [Related]
11. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693 [TBL] [Abstract][Full Text] [Related]
12. [Effects of new antineoplastic agents (dimethoxybenflurone and Oracin) on the cardiovascular system and other parameters in the rabbit in vivo]. Machácková J; Gersl V; Adamcová M; Mazurová Y; Hrdina R; Mĕlka M; Nobilis M Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):119-38. PubMed ID: 11413675 [TBL] [Abstract][Full Text] [Related]
13. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Elbl L; Hrstkova H; Tomaskova I; Michalek J Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614 [TBL] [Abstract][Full Text] [Related]
14. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy]. Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670 [TBL] [Abstract][Full Text] [Related]
15. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276 [TBL] [Abstract][Full Text] [Related]
16. Protein profiling in daunorubicin-induced cardiomyopathy. Adamcová M; Pelouch V; Gersl V; Kaplanová J; Mazurová Y; Simůnek T; Klimtová I; Hrdina R Gen Physiol Biophys; 2003 Sep; 22(3):411-9. PubMed ID: 14986890 [TBL] [Abstract][Full Text] [Related]
17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L; Bramwell V; Moran LA Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762 [TBL] [Abstract][Full Text] [Related]
18. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Pouillart P Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396 [TBL] [Abstract][Full Text] [Related]